Human T cell responses to Japanese encephalitis virus in health and disease by Turtle, L et al.
Page 1 
Human T cell responses to Japanese encephalitis virus in health and 1 
disease 2 
 3 
JEM manuscript ID: 20151517 4 
 5 
Short title: T cells in Japanese encephalitis 6 
 7 
Turtle L1,2,3*   Wellcome Trust Clinical Research Fellow 8 
Bali T4    Research Assistant 9 
Buxton G1   Clinical Research Fellow 10 
Chib S4   Postdoctoral Research Assistant 11 
Chan S4   Coordinator 12 
Soni M4   Coordinator 13 
Hussain M5   Technician 14 
Isenman H1   Clinical Research Fellow 15 
Fadnis P6   PhD Student 16 
Venkataswamy M6  Senior Scientific Officer 17 
Satishkumar V5,7  Study Physician 18 
Lewthwaite P8  Consultant Physician 19 
Kurioka A9   PhD student  20 
Krishna S5   Head of Microbiology 21 
Veera Shankar M7  Head of Paediatrics 22 
Ahmed R7   Assistant Professor of Paediatrics 23 
Begum A5,7   Community Medical Officer 24 
Ravi V6    Professor of Neurovirology 25 
Desai A6   Professor of Neurovirology 26 
Yoksan S10   Associate Professor 27 
Fernandez S11  Virology Section Chief 28 
Willberg C9   Senior Scientist 29 
Kloverpris, H9  Postdoctoral Scientist 30 
Conlon C9   Professor of Infectious Diseases 31 
Klenerman P9§*  Professor of Immunology 32 
Satchidanandam V4§ Professor 33 
Solomon T1,2,12§  Professor of Neuroscience 34 
 35 
* Corresponding authors 36 
§ These authors contributed equally 37 
 38 
Affiliations: 39 
 40 
1 Institute of Infection and Global Health, University of Liverpool, 8 West Derby Street, 41 
Liverpool, L69 7BE, UK. +44 151 795 9626 42 
2 Health Protection Research Unit for Emerging and Zoonotic Infections, University of 43 
Liverpool, L69 7BE, UK. 44 
3 Tropical & Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, L7 45 
8XP 46 
4 Dept of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, 47 
India. +91 80-22932685 48 
Page 2 
5 Dept of Microbiology, Vijayanagar Institute of Medical Science (VIMS) Medical College, 49 
Hospet Road, Bellary, 583104, India. +91 8392 235 288 50 
6 Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), 51 
Bangalore, 560029, India. +91 80 2699 5126 52 
7 Dept of Paediatrics, VIMS Medical College, Bellary, 583104, India. +91-8392-583104 53 
8 Consultant Infectious Diseases, Dept of Infection & Travel Medicine, St James’s 54 
University Hospital, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF 55 
+44 113 20  66614 56 
9 Nuffield Dept. of Medicine, University of Oxford, Peter Medawar Building for Pathogen 57 
Research, Oxford, OX1 3SY, UK. +44 1865 281885 58 
10 Centre for Vaccine Development, Institute of Molecular Biosciences, Mahidol University 59 
at Salaya, Bangkok, Thailand. +662-441-9337 60 
11 Dept of Virology, Armed Forces Research Institute of Medical Science (AFRIMS), 61 
Bangkok 10400, Thailand. +66 2 6962700 62 
12 Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK 63 
 64 
 65 
 66 
Abbreviations: 67 
C   Core protein 68 
CSF   Cerebrospinal fluid 69 
CFSE   Carboxyfluorescein succinimidyl ester 70 
DENV   Dengue virus 71 
DF   Dengue fever 72 
DHF   Dengue haemorrhagic fever 73 
DMSO  Dimethylsulphoxide 74 
E   Envelope protein 75 
IISc   Indian Institute of Science 76 
IQR   Interquartile range 77 
JE   Japanese encephalitis 78 
JEV   Japanese encephalitis virus 79 
MIP   Macrophage inflammatory protein 80 
NAb   Neutralising antibody 81 
NIMHANS  National Institute of Mental Health and Neurosciences 82 
NS   Non-structural protein 83 
prM   Pre-membrane protein 84 
PRNT   Plaque reduction neutralisation titre 85 
SFC   Spot forming cells 86 
TCL   T cell line 87 
WNV   West Nile virus 88 
VIMS   Vijayanagar Institute of Medical Science 89 
YFV   Yellow fever virus 90 
ZIKV   Zika virus 91 
 92 
  93 
Page 3 
Abstract 94 
 95 
Japanese encephalitis (JE) virus (JEV) is an important cause of encephalitis in children of 96 
South and Southeast Asia. However, the majority of individuals exposed to JEV only 97 
develop mild symptoms associated with long-lasting adaptive immunity. The related 98 
flavivirus dengue (DENV) co-circulates in many JEV endemic areas and clinical data 99 
suggest cross-protection between DENV and JEV. To address the role of T cell responses 100 
in protection against JEV, we conducted the first full-breadth analysis of the human 101 
memory T cell response using a synthetic peptide library. Ex-vivo interferon-γ responses 102 
to JEV in healthy JEV-exposed donors were mostly CD8+ and targeted non-structural (NS) 103 
proteins, whereas interferon-γ responses in recovered JE patients were mostly CD4+ and 104 
targeted structural proteins and the secreted protein NS1. Amongst patients, a high 105 
quality, polyfunctional CD4+ T cell response was associated with complete recovery from 106 
JE. T cell responses from healthy donors showed a high degree of cross-reactivity to 107 
DENV which was less apparent in recovered JE patients, despite equal exposure. These 108 
data reveal divergent functional CD4+ and CD8+ T cell responses linked to different clinical 109 
outcomes of JEV infection, associated with distinct targeting and broad flavivirus cross-110 
reactivity including epitopes from DENV, West Nile and Zika virus. 111 
 112 
  113 
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Introduction 114 
 115 
Japanese encephalitis (JE) virus (JEV) is a member of the family Flavivirus, genus 116 
Flaviviridae. JEV is an arthopod-borne virus (arbovirus) endemic to rural parts of South 117 
and Southeast Asia. JE is the most commonly diagnosed encephalitis in Asia, and is an 118 
important cause of disability and death in children in this region. Only around 0.1-1% of 119 
JEV infections of humans result in encephalitis (Halstead and Grosz, 1962). The 120 
remainder are clinically silent or result in a mild febrile illness (Watt and Jongsakul, 2003). 121 
The overwhelming majority of JEV-exposed individuals thus develop long-lasting naturally 122 
induced adaptive immunity, although this wanes in later life (Solomon, 2004). 123 
 124 
JEV is a single stranded, positive sense RNA virus; the single 10 kb open reading frame 125 
(ORF) encodes three structural proteins, envelope (E), (pre-)Membrane (prM/M) and core 126 
(C); and seven non-structural (NS) proteins designated NS1, NS2A, NS2B, NS3, NS4A, 127 
NS4B and NS5 (Sumiyoshi et al., 1987). There are an estimated 68 000 cases of JE 128 
annually, and probably around 17 000 deaths (Campbell et al., 2011). Clinical outcomes 129 
vary from complete recovery, through recovery with neuropsychiatric sequelae to death 130 
(Solomon et al., 2002). The role of the immune response to JEV in determining whether 131 
infection is asymptomatic or results in disease is incompletely understood. 132 
 133 
Protection by neutralising antibody (NAb) to JEV in animal models is well established, 134 
whether passively administered, pre-formed by immunisation, or rapidly developed after 135 
challenge by a memory response (Gao et al., 2010; Konishi et al., 1999; Larena et al., 136 
2011; Van Gessel et al., 2011). Higher titres of JEV NAb correlate with better protection 137 
(Lubiniecki et al., 1973). Development of JEV NAb after vaccination correlates with 138 
protection in humans (Hoke et al., 1988) and an anamnestic antibody response is 139 
associated with good outcome from disease (Libraty et al., 2002; Winter et al., 2004). 140 
Conversely, low JEV antibody levels in serum and cerebrospinal fluid (CSF) of patients 141 
with JE are associated with death (Libraty et al., 2002; Solomon et al., 2002). 142 
 143 
Cell mediated immunity to JEV is less well studied. Observations from animal models 144 
suggest that T cells play a subsidiary role in protection from JE but could also contribute to 145 
immunopathology (Larena et al., 2011). Adoptive transfer of primed T cells can protect 146 
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animals from intracerebral JEV challenge (Murali-Krishna et al., 1996), even in the 147 
absence of antibody in some cases (Ashok and Rangarajan, 1999). 148 
 149 
Lymphocyte responses to JEV have been detected in humans for many years (Chaturvedi 150 
et al., 1979; Konishi et al., 1995). Studies of healthy JEV-exposed residents of endemic 151 
areas demonstrated CD4+ and CD8+ T cell responses to several JEV proteins dominated 152 
by NS3, especially amino acids 193 - 324 (Kumar et al., 2004c). In recovered JE patients 153 
IFNγ responses to NS3 amino acids 193 - 324 were infrequent and smaller than in healthy 154 
JEV-exposed controls, despite proliferative responses being preserved (Kumar et al., 155 
2004b). Low IFNγ production was associated with poor outcome, indicating a role for IFNγ 156 
in recovery from JE. However, other cytokine responses and responses to other JEV 157 
proteins have not been examined in JE patients. 158 
 159 
JEV co-circulates with other flaviviruses in much of South and Southeast Asia, notably the 160 
four serotypes of dengue virus (DENV). Prior DENV exposure reduces the severity of JE 161 
(Edelman et al., 1975; Libraty et al., 2002); however the effect of JEV immunity on 162 
subsequent DENV infection is less clear. A large study of an inactivated JE vaccine in 163 
Thailand showed those patients who developed dengue haemorrhagic fever (DHF) had 164 
lower illness severity scores if they had received JE vaccine, suggesting a beneficial effect 165 
(Hoke et al., 1988). On the other hand, a later careful prospective study in the same 166 
location showed that the presence of JEV NAb at the study entry (in the absence of DENV 167 
NAb) gave a 2.75 fold increase in the risk of dengue fever (DF) (Anderson et al., 2011). 168 
 169 
DENV infection primes broadly cross-reactive T cell responses; such responses between 170 
DENV serotypes have been studied extensively, particularly with reference to DHF 171 
(Rothman, 2010). Limited data suggest that cross-reactive T cell responses between JEV 172 
and DENV exist in inactivated JE vaccine recipients (Aihara et al., 1998). However, the 173 
potential for cross-reactive T cell responses between JEV and other flaviviruses after 174 
natural infection and their potential for protection is not known. 175 
 176 
Taken together, the available data suggest that T cell responses could be protective in 177 
human JE; however, no study to date has compared responses across the entire length of 178 
the JEV polyprotein between encephalitis and asymptomatic infection. Moreover, many of 179 
the published DENV epitopes show marked similarity to the corresponding sequences in 180 
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JEV, suggesting that immunological cross recognition by T cells is theoretically possible. 181 
Given that 1) prior DENV infection is protective in JE and 2) DENV infection primes 182 
broadly cross-reactive T cells, we hypothesised that, in regions endemic to both viruses, 183 
patients who had suffered from JE would have memory T cell responses that had less 184 
cross-reactivity with DENV than healthy JEV-exposed subjects. Therefore, we undertook a 185 
study to systematically map JEV epitopes using a full length synthetic peptide library for 186 
JEV.  We assessed the specificity, function and magnitude of the T cell response and 187 
measured the degree of T cell receptor cross-reactivity in healthy JEV-exposed donors 188 
and recovered JE patients. 189 
 190 
  191 
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Results 192 
 193 
Subjects 194 
 195 
The study took place in Karnataka State, South India, a JE endemic area. One hundred 196 
and three participants were recruited into the study (table I). Fifty-one were healthy Indian 197 
residents of JEV endemic areas, 39 were recovered JE patients. Healthy donors were 198 
recruited in Bangalore and at Vijayanagar Institute of Medical Sciences (VIMS), Bellary; 199 
recovered JE patients were recruited at VIMS. Thirty-five healthy donors (69%) were 200 
defined as JEV-exposed on the basis of residence in a JEV endemic area during 201 
childhood and a positive NAb assay. A training cohort of 13 participants was recruited in 202 
the UK, comprising a mixture of flavivirus exposed and unexposed subjects. Two subjects 203 
recruited in the UK reported classical dengue illness (1 DF, 1 DHF) with positive DENV 204 
IgM, and one more without diagnostic testing; all three had acquired infection in dengue 205 
endemic areas and were anti-DENV NAb positive. 206 
 207 
T cell responses in healthy JEV-exposed subjects are dominated by diverse, highly cross-208 
reactive, CD8+ cells 209 
 210 
Thirty-five JEV NAb+ healthy South Indian donors were screened by enzyme linked 211 
immunospot (ELISpot) assay or whole blood intracellular cytokine staining (WB ICS) for 212 
JEV T cell responses. Seventeen (49%) showed positive ex-vivo IFNγ assays (Fig 1 A & 213 
B). In a subset of 24 subjects tested, 22 (92%) showed proliferative responses (Fig 1 C). 214 
IFNγ responses were predominantly directed against NS3, NS4 and NS5 (Fig 1 A) and 215 
were modest in size (Fig 1 B), whereas proliferative responses recognised all viral proteins 216 
(Fig 1 C). Flow cytometric analysis showed 80% of ex-vivo IFNγ responses were CD8+ 217 
(Fig 1 D). 218 
 219 
Clinical data suggest cross protection between DENV and JEV. Two subjects with 220 
documented dengue illness (but who were unlikely to have been JEV-exposed) and one 221 
JEV NAb negative volunteer showed IFNγ ELISpot responses to the JEV peptide library 222 
(shown in red in Fig 1 B) - no responses were detected in healthy DENV and JEV 223 
unexposed controls (unpublished data). The two subjects reporting dengue were also 224 
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positive for JEV NAb, though anti-DENV titres were higher, consistent with prior DENV 225 
infection (JEV 50% plaque reduction neutralization titer [PRNT50] 1 in 266 and 1 in 85 and 226 
DENV PRNT50 1 in 4,515 [DENV1] and 1 in 12,413 [DENV3], respectively). Therefore, we 227 
set out to determine whether JEV and DENV responses cross-react. First, responses were 228 
mapped by ELISpot or by expanding short term T cell lines from donors showing ex-vivo 229 
responses followed by deconvolution of pools in ICS assays. Next, cross-reactivity was 230 
tested using variant peptides from DENV (and other flaviviruses) corresponding to the 231 
mapped peptides of JEV.  232 
 233 
Using this approach, we first studied two naturally JEV-exposed subjects (H001/1 and 234 
H008/4) and one reporting DF (H001/4) in detail. CD8+ T cell responses were identical in 235 
size and functional characteristics to peptide sequence variants from other flaviviruses (Fig 236 
2 A top panels & B). T cell lines showed similar responses in functional assays whichever 237 
peptide was tested (Fig 2 A bottom panels), irrespective of which peptide was used to 238 
expand the line (Fig 2 C). Titrations of variant peptides showed responses detectable in 239 
the nanomolar range and that cross-reactivity was not limited to high peptide concentration 240 
(figures 2B & C), although there was some variation in efficiency of individual peptides. 241 
 242 
We then extended this analysis across the cohort; using peptides of West Nile virus 243 
((WNV), a flavivirus closely related to JEV); DENV2, and E, NS1, NS3 and NS5 proteins 244 
from DENV1, 3 and 4 (see materials and methods). Once library peptides were mapped, 245 
the same T cell lines were then tested against the equivalent peptides from DENV1-4 and 246 
WNV, based on a ClustalW alignment of the library polyprotein sequence (an example is 247 
shown in Fig 2 D). Responses to the variant peptides were normalised across different 248 
assays by dividing the result by the value for JEV peptide in the same assay, a cross-249 
reactivity index of 1 indicating an equal response to JEV and variant peptides. In five 250 
subjects, cross-reactive responses tested both ex-vivo and on T cell lines showed good 251 
agreement (Fig 2 E). Next, we studied 10 healthy JEV-exposed donors in whom 15 252 
epitopes were mapped. In all but three, responses were highly cross-reactive (Fig 2 F) and 253 
were not significantly different from the hypothetical value of 1 (indicating equivalent 254 
responses) by Wilcoxon signed rank test. Eight out of the 10 donors showing responses 255 
that recognised peptides from at least two other flaviviruses (often more) as efficiently as 256 
JEV. 257 
 258 
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Cross-reactivity was confirmed by dual tetramer staining between the JEV epitope and 259 
three variant epitopes from WNV, DENV-1 and DENV-2/3 (Fig 2 G), at least in one 260 
individual. Cross-reactivity occurred at the single cell level with apparently equal affinity 261 
(Fig 2 H). Finally, to determine past exposure to DENV, PRNT50 to DENV1-4 were 262 
measured in those subjects who had cross-reactivity assays performed; the cohort was 263 
extensively DENV exposed (Fig 2 I). 264 
 265 
Overall, these experiments confirmed clear JEV-specific T cell memory responses in JEV 266 
NAb positive subjects from a JE endemic area. These responses were predominantly 267 
CD8+, highly cross-reactive among flaviviruses and mostly targeted NS proteins, including 268 
in donors with clear DENV exposure. 269 
 270 
CD8+ T cell responses in healthy JEV-exposed subjects are polyfunctional and show a 271 
cytotoxic phenotype 272 
 273 
We next addressed the functionality of these responses. We asked whether cytokines 274 
were co-secreted by JEV-specific T cells using WB ICS assays; example flow cytometry 275 
data are shown in Fig 3 A. The CD8+ T cell response was dominated by IFNγ+/TNFα+/MIP-276 
1β+ and IFNγ+/TNFα+ cells (Fig 3 B). Overall 75% of the responding cells made >1 277 
cytokine. The small number of CD4+ T cell responses precluded this analysis for this 278 
population; CD4+ T cell responses were smaller as well as less frequently detected (Fig 3 279 
C). 280 
 281 
To address the production of other cytokines, bead array assays were performed in a 282 
subset of 13 donors on day 2 and day 5 supernatants from proliferation assays showing 283 
the largest responses, which were often different pools from the ex-vivo IFNγ assays (Fig 284 
3 D, data for day 5). This showed some evidence of more diverse cellular responses with 285 
release of IL10 (the cytokine most frequently detected in these assays) in 11 (85%) of the 286 
donors (Fig 3 D & E); IL4 and IL13 were also detected but in much smaller amounts and 287 
less frequently. Other T cell derived cytokines and chemokines were detected infrequently; 288 
five subjects (39%) made either CCL3 or CCL5 responses and only two subjects (15%) 289 
made IL17A (Fig 3 E). 290 
 291 
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In selected individuals, where re-sampling was possible after CD8+ T cell responses were 292 
mapped, the cytotoxic capacity of these cells was studied in more detail. JEV-specific 293 
CD8+ T cell responses degranulated in response to peptide stimulation (Fig 4 A) and 294 
degranulation responses were cross-reactive (Fig 4 A - C). Responses were detectable to 295 
at least 10nM peptide ex-vivo indicating that they are likely to be functional in-vivo (Fig 4 296 
C). Responding cells expressed perforin and granzyme B (figures 4D - F) consistent with 297 
killing capacity. To confirm these results short term T cell lines were expanded to 298 
responding peptides: these too degranulated (Fig 4 G) and were cross-reactive between 299 
JEV and DENV (Fig 4 H). Cross-reactive degranulation responses were equivalent in 300 
overall functionality between JEV and DENV, with 55-60% of responding cells 301 
degranulating in both cases (Fig 4 I). Finally, cross-reactive CD8+ T cell lines were able to 302 
kill peptide loaded cells, whether expanded to JEV or DENV peptides (Fig 4 J). 303 
 304 
Screening for T cell responses in convalescent JE patients 305 
 306 
We next addressed T cell responses in recovered JE patients. Thirty-nine recovered JE 307 
patients were screened by ELISpot or WB ICS; 28 (72%) showed ex-vivo IFNγ responses. 308 
Sample flow cytometry data are shown in Fig 5 A. Ex-vivo IFNγ responses targeted all 309 
JEV proteins (Fig 5 B), with slightly more responses against the C/prM and NS1/NS2 310 
pools. Around 80% of the IFNγ response came from CD4+ T cells (Fig 5 C), several 311 
donors showed exclusively CD4+ responses. Proliferative responses were similarly 312 
distributed among JEV proteins (Fig 5 D & E). Responding peptides were mapped using 313 
short term T cell lines using the same strategy as the healthy JEV-exposed donors, and 14 314 
peptides from 7 recovered patients were tested in cross-reactivity assays (Fig 5 F). 315 
Mapped responses in recovered JE patients were mostly JEV-specific, and showed a 316 
cross-reactivity index significantly different from the hypothetical value of 1 (indicating 317 
equivalent responses) by Wilcoxon signed rank test in all cases except DENV1, which 318 
approached significance despite fewer variant peptides tested. Importantly, NAbs to DENV 319 
were present in all the recovered JE patients with peptides mapped and cross-reactivity 320 
assays performed (Fig 5 G and table I), suggesting the lack of cross-reactivity in recovered 321 
JE patients is not a result of lack of DENV exposure. In the same subset, JEV NAb titres 322 
were also tested and showed no difference between the good outcome and poor groups 323 
(Fig 5 H). 324 
 325 
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A polyfunctional, IFNγ-dominated CD4+ T cell response correlates with better clinical 326 
outcome in convalescent JE patients 327 
 328 
JE patients were categorised into good outcome, (complete recovery with no neurological 329 
deficit; Liverpool outcome score 5) or poor outcome (incomplete recovery - Liverpool 330 
outcome score 2-4 or abnormal neurological examination, see methods). There was no 331 
difference in targeting of viral proteins or proportion of the response expressed by CD4+ T 332 
cells when analysed by outcome (unpublished data). IFNγ ICS responses, however, were 333 
larger in patients with good outcome (Fig 6 A). TNFα production was equivalent between 334 
the two groups (Fig 6 B), but was derived mostly from TNFα single positive cells in those 335 
with poor outcome (Fig 6 C). Complete recovery was strongly associated with a 336 
polyfunctional IFNγ+/IL2+/TNFα+ CD4+ T cell response, indicating that a poor quality 337 
memory response, which is pro-inflammatory, but lacking in anti-viral/helper capacity, is 338 
associated with recovery from JE with long term neurological damage. 339 
 340 
To explore cytokine production further, in a subgroup of 11 patients, secreted cytokine 341 
responses were assayed from the day 2 and day 5 supernatants of proliferation assays as 342 
for the healthy JEV-exposed group (Fig 6 D, data for day 5). In these assays across both 343 
time-points IL10 and IL13 were detected in several patients from both groups (Fig 6 D & E) 344 
and proinflammatory TNFα responses were frequent. Similar to the healthy group, other T 345 
cell derived cytokine and chemokine responses were rare. Three subjects made CCL3 or 346 
CCL5 responses and three made IL17A. Looking specifically at CD8+ T cell responses in 347 
recovered JE patients by WB ICS, these were mostly polyfunctional and characterised by 348 
IFNγ+/TNFα+/MIP-1β+ and IFNγ+/TNFα+ cells (Fig 6 F). 349 
 350 
Importantly, all the patients were sampled at least 6 months from acute illness, by which 351 
time most recovery is expected to have occurred. Time from illness to sampling was the 352 
same in both groups (Fig 6 G), indicating that this variable did not confound the results. 353 
Interestingly, the observed defect in CD4+ T cell cytokine production was not apparent in 354 
proliferative responses which were equal in magnitude between the two groups; CD8+ 355 
proliferative responses were slightly larger in those with poor outcome (Fig 5 E). Overall, 356 
these results indicated that T cell responses in patients who have recovered from JE were 357 
predominantly CD4+ and JEV-specific. Smaller IFNγ responses in conjunction with poor 358 
quality, pro-inflammatory (TNFα+) CD4+ responses were associated with poor outcome. 359 
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 360 
T cell responses are differentially targeted in JE patients and healthy donors 361 
 362 
During screening, ex-vivo IFNγ responses in healthy JEV-exposed donors were directed 363 
mostly at NS3, NS4 and NS5 (Fig 1 A), whereas recovered JE patients responded to all 364 
JEV proteins (Fig 5 B). Mapped peptides were plotted according to their location in the 365 
JEV polyprotein for healthy, JEV-exposed donors (Fig 7 A), recovered JE patients (Fig 7 366 
B) and two UK participants reporting dengue illness (Fig 7 C). Sequences of all the JEV 367 
peptides identified are in table II and the variant peptides showing responses in cross-368 
reactivity assays are shown in table III. Almost all the mapped responses in structural 369 
proteins were identified in JE patients, and one healthy JEV-exposed donor showed a 370 
CD4+ response to E protein of JEV (Fig 7 A & B, table II). In contrast, the responses in 371 
healthy JEV-exposed donors were focused on NS3 and NS5, and only one peptide was 372 
successfully mapped in NS3 in a JE patient. This was despite multiple attempts at 373 
expanding T cell lines to NS3 in vitro, which failed to produce responses in all except one 374 
individual. The two subjects reporting dengue illness showed similar findings to the healthy 375 
JEV-exposed donors (Fig 7 C). The average Shannon entropy (H Index) of Indian isolates 376 
of JEV and DENV corresponding to the position of JEV peptides eliciting T cell responses 377 
in recovered JE patients was significantly greater than in healthy JEV-exposed donors, p = 378 
0.0003 (Fig 7 F), indicating that heathy donors target conserved regions of the flavivirus 379 
polyprotein. 380 
 381 
The absence of T cell responses in NS1 in the healthy JEV-exposed donors could not be 382 
explained by a lack of potential HLA-binding motifs. The HLArestrictor server (Erup Larsen 383 
et al., 2011) identified 122 HLA class I binding motifs for the alleles identified ranked 384 
“strong binder” with a predicted accuracy of > 80%. A more limited analysis of the HLA 385 
class II DRB1 alleles 03:01, 04:01, 07:01, 11:01 and 15:01 using SYFPETHI (Rammensee 386 
et al., 1999) showed 197 15-mer peptides with score ≥ 20. 387 
 388 
Few peptides were identified in more than one individual despite overlap of HLA alleles 389 
across the cohort (table II). One exception was peptide TMAMTDTTPFGQQRVFK at 390 
position 2869 to 2885 of the viral polyprotein (NS5 amino acids 342 - 358) which showed 391 
CD8+ T cell responses in three healthy JEV-exposed donors and one DENV-exposed 392 
donor. This corresponds to a highly conserved 20 amino acid segment which is nearly 393 
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identical across all the medically important mosquito borne flaviviruses, visible as a trough 394 
in Shannon entropy (H index) in NS5 (Fig 7 D). In our study, three healthy HLA A*68:01 395 
positive JEV-exposed donors who recognised JEV NS5 342 - 358 also recognised DENV 396 
peptides that were truncated for the C terminal three amino acids (Fig 2 D), suggesting 397 
they were recognising DTTPFGQQR, previously described as one of the most 398 
immunogenic DENV CD8+ T cell epitopes out of 408 identified (Weiskopf et al., 2013). In a 399 
fourth, DENV exposed, HLA B*35:01 positive subject (H010/4), the JEV NS5 342 - 358 400 
response was mapped to TPFGQQRVF (table II), also previously shown to be presented 401 
by this allele (Rivino et al., 2013). 402 
 403 
These data suggest that T cell responses from recovered JE patients target JEV-specific 404 
regions that are less conserved among flaviviruses (high H index). Healthy JEV-exposed 405 
donors made responses against conserved regions, that were highly cross-reactive among 406 
different flaviviruses (Fig 2 F). 407 
  408 
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Discussion 409 
 410 
In this study we have presented data showing that across the entire JEV polyprotein 411 
memory T cell responses in healthy JEV-exposed donors are (i) predominantly directed 412 
against NS3, NS4 and NS5, (ii) are CD8+ and (iii) cross-react extensively between 413 
flaviviruses. Recovered JE patients, on the other hand, mount mostly JEV-specific CD4+ T 414 
cell responses and target epitopes predominantly within the JEV structural proteins and 415 
the secreted protein NS1. Among the recovered JE patients, the quality of the ex-vivo 416 
CD4+ T cell response was associated with outcome; in individuals with poor outcome, the 417 
presence of a significant TNFα+-only CD4+ T cell population suggests a potential 418 
mechanism whereby T cells might contribute to damaging inflammation in JE. These data 419 
are compatible with the notion, supported by animal studies (Larena et al., 2011; Larena et 420 
al., 2013), that T cells may play a role both in protection and immunopathology in JE. In 421 
addition this study describes the first polyfunctional T cell responses to JEV, the first 422 
minimal epitopes of JEV in humans and the first demonstration of cytotoxic CD8+ T cell 423 
responses to JEV in naturally exposed individuals. 424 
 425 
Anti-viral T cells exhibiting multiple functions are well described after many viral infections, 426 
and have been observed after infection or vaccination with several flaviviruses (Akondy et 427 
al., 2009; Friberg et al., 2011b; Piazza et al., 2010). In this study we have described 428 
polyfunctional T cell responses to JEV in both CD4+ and CD8+ subsets and found that the 429 
quality of the CD4+ T cell response was the factor most strongly associated with complete 430 
recovery from JE. Evidence for the protective capacity of polyfunctional T cell responses in 431 
humans is largely correlative (Betts et al., 2006), as is the case here. On average, >50% of 432 
the responding cells expressed two or more cytokines and the subjects in this study were 433 
sampled a median of 6 years or more after the viral encounter. Therefore, these responses 434 
likely reflect a long lived stable memory population rather than newly responding or 435 
terminally differentiated single cytokine positive cells (Seder et al., 2008). 436 
 437 
In a subgroup of subjects, CD8+ T cell degranulation responses were studied. Sampling 438 
limitations meant we could not test these responses in the whole cohort, but in all the 439 
subjects tested, CD8+ T cells degranulated in response to JEV peptides in the 10nM 440 
range. Degranulation, perforin and granzyme B expression correlates closely with the 441 
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ability to kill (Betts et al., 2003; Pardo et al., 2004); which we have confirmed using peptide 442 
loaded cells. These cytotoxic responses also cross-react between JEV and DENV; in other 443 
words a DENV primed cell could in principle kill a JEV infected target or vice versa. Killing 444 
of cells expressing Pox virus vectored JEV prM/E/NS1 proteins has previously been 445 
demonstrated for CD4+ T cell clones and CD8+ short term T cell lines expanded from 446 
PBMC from JE vaccinated subjects, rather than natural JEV exposure (Aihara et al., 1998; 447 
Konishi et al., 1998). Although we have not shown killing of virally infected target cells 448 
(itself a surrogate marker of protection), the data presented here make it highly likely that 449 
these responses would be capable of killing JEV infected cells. T cell killing of JEV 450 
infected cells, to our knowledge, has only been shown for murine and never for human 451 
cytotoxic T lymphocytes (Murali-Krishna et al., 1994). 452 
 453 
Previous work in the same location found a higher frequency of responses to NS3 (Kumar 454 
et al., 2004a; Kumar et al., 2004b), likely accounted for by the time interval between 455 
exposure and testing. The patients in our study were sampled on average 6 years after 456 
JE, whereas in the studies of Kumar et al. (2004b) they were sampled around 6 months 457 
after disease. In the case of DENV, when patients are sampled two weeks after illness, the 458 
frequency of responses to NS3 reported is as high as 90% (Duangchinda et al., 2010). In 459 
recovered JE patients, IFNγ ELISpot responses to NS3 were small (unpublished data), 460 
and repeated attempts at in vitro expansion of responding T cells to NS3 consistently 461 
failed to produce responses in IFNγ+/TNFα ICS assays. Taken together, our results are 462 
consistent with earlier findings, that JE patients had defective IFNγ but preserved 463 
proliferation responses to JEV NS3 amino acids 193-324 (Kumar et al., 2004b). Now we 464 
have also shown reduction in IFNγ is a general phenomenon associated with poor 465 
outcome from JE, and occurs in response to all JEV proteins not only NS3, increasing the 466 
likelihood that this is a biologically relevant result. In addition, we have extended these 467 
findings to show that an unbalanced CD4+ T cell response characterised by pro-468 
inflammatory TNFα production, in the absence of sufficient additional helper/anti-viral IL2 469 
and IFNγ, is strongly associated with poor outcome from JE. 470 
 471 
We observed a striking degree of cross-reactivity in the NS protein specific short term 472 
CD8+ T cell lines from healthy JEV-exposed donors. The average Shannon entropy of 473 
sequences recognised by this group was low, indicating they were highly conserved. A 474 
recent study on dengue also found the majority of conserved CD8+ T cell epitopes are 475 
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found in the NS proteins (Weiskopf et al., 2015). Short term T cell lines from some healthy 476 
donors in our study recognised peptides from flaviviruses for which the chance of 477 
exposure was extremely remote, such as tick borne encephalitis virus and St Louis 478 
encephalitis virus (unpublished data), and some sequences were in common with 479 
geographically diverse viruses such as Murray Valley encephalitis virus and Zika virus, 480 
suggesting that this phenomenon goes beyond simply exposure and is largely accounted 481 
for by selective targeting of conserved regions. The dominant responses in recovered JE 482 
patients, on the other hand, cross-reacted much less with variant peptides from DENV and 483 
WNV. DENV NAb assays revealed this was not simply due to a lack of exposure. CD4+ T 484 
cells dominated the responses in recovered JE patients, this cannot account for the lack of 485 
cross-reactivity because CD4+ T cells are known to mount cross-reactive responses to 486 
flaviviruses (Aihara et al., 1998; Kurane et al., 1991). Although the cross-reactivity of T cell 487 
responses appeared to differ between healthy JEV-exposed donors and recovered 488 
patients, the retrospective nature of this study and the likely difference in time between 489 
exposure and sampling for these different groups limits our ability to assign a protective 490 
role to these responses. 491 
 492 
Both serotype specific and serotype cross-reactive T cell responses are readily detectable 493 
after a single DENV infection (Friberg et al., 2011a), and, over subsequent DENV 494 
exposures, the response may be skewed towards more conserved epitopes (Weiskopf et 495 
al., 2013). The exposure to DENV and the highly cross-reactive T cell responses in the 496 
healthy JEV-exposed donors in this study is consistent with these findings, and suggest 497 
this phenomenon is not restricted to DENV. Given the protective effect of DENV on JEV 498 
(Edelman et al., 1975), one possibility is that exposure to DENV primes JEV cross-reactive 499 
T cell responses. Although there are well described examples of pathology mediated by 500 
DENV cross-reactive T cells (Mongkolsapaya et al., 2003), not all studies on dengue have 501 
confirmed the relationship between cross-reactive T cells and disease (Friberg et al., 502 
2011a), and some observations imply a protective role for cross-reactive memory T cells 503 
(Hatch et al., 2011; Weiskopf et al., 2013). Similarly, animal models of sequential T cell 504 
priming and challenge can show either impaired or enhanced protection (Welsh et al., 505 
2010). JE pathogenesis is distinct from some other viral infections in that viraemia is 506 
typically very low and often clinically inapparent; therefore an early, modestly sized, cross-507 
reactive CD8+ T cell response in the periphery may prevent dissemination to the central 508 
nervous system and limit the virus to a compartment where it is not particularly pathogenic. 509 
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The retrospective nature of this study means we are unable to address this question 510 
directly, but this could be the subject of future prospective studies. 511 
 512 
There are several possible reasons for the limited flavivirus cross-reactive T cell responses 513 
seen in recovered JE patients even years after disease and despite DENV exposure. 514 
There may be intrinsically pathogenic responses in the context of disease that are different 515 
from those in health, and age at exposure or variation in innate immunity may affect the 516 
character of responses. Also, the order of priming may affect the cross-reactivity of T cell 517 
responses. Support for this is found in epidemiological observations that DENV infection is 518 
at least partially protective against JE (Edelman et al., 1975; Libraty et al., 2002) and that 519 
JEV NAb (but not vaccination) has a detrimental effect on DENV (Anderson et al., 2011). 520 
However, a weakness of our study (common to many) is that we cannot determine the 521 
order in which different flaviviruses were encountered and therefore cannot provide direct 522 
evidence that JEV priming modifies DENV responses. Future prospective studies could 523 
address this question, and investigate differences in the T cell response as a potential 524 
mechanism. 525 
 526 
Ex-vivo responses in recovered JE patients against the structural proteins and the pool 527 
containing NS1 were frequently observed, but were rare in the healthy JEV-exposed 528 
donors. It is hypothesized based on observations in DF that structural proteins and the 529 
secreted protein NS1 interact with B cells and elicit CD4+ responses, whereas the 530 
remaining non-structural proteins elicit mostly CD8+ T cell responses (Rivino et al., 2013), 531 
consistent with what we have seen in this study. The reasons underlying the absence of 532 
responses to NS1 in the healthy JEV-exposed donors are not clear, but previous work in 533 
this region identified T cell responses against NS1 in healthy children (Kumar et al., 534 
2004a) so anti-NS1 responses are likely not intrinsically pathogenic. 535 
 536 
Whilst the dominant responses mapped in recovered JE patients were directed against 537 
less conserved viral proteins, we nevertheless identified a number of IFNγ responses 538 
against NS3, NS4 and NS5. One CD8+ T cell response from a recovered JE patient 539 
(JE098/2) targeted a conserved epitope (ELGEAAAIFMTATPP, NS3 306-320), which 540 
showed a cross-reactive response in subject H013/3 (these two subjects shared HLA 541 
02:01 and B40:01, as well as being closely matched at B35:01 and B35:03; table II). This 542 
response was not further tested in JE098/2 (due to insufficient cells), but it is likely that this 543 
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response would have been cross-reactive. Although the predominance of JEV-specific 544 
responses in recovered JE patients is likely explained by variation in amino acid 545 
sequences between JEV and DENV, in some cases single amino acid changes (aside 546 
from anchor residues) had very profound effects on responses. For example, changing Ala 547 
at position 5 of GEAAAIFMT to Gly completely abolished CD8+ T cell recognition in donor 548 
H013/3. In donor JE054/2, changing Leu to Ile (a very modest alteration) at position 12 of 549 
peptide AISGDDCVVKPLDDRF made no difference whilst changing Asp to Glu (also 550 
similar amino acids) at position 14 eliminated the CD8+ T cell response. On the other 551 
hand, two amino acid changes from the HLA B*08:01 restricted epitope DLMCHATF 552 
(DENV) to DVMCHATL (JEV) gave rise to identical CD8+ T cell responses in donor 553 
H001/4 (who reported dengue illness) and a wide range of single amino acid variants from 554 
Gln at position 8 of the HLA B*58:01 restricted epitope MTTEDMLQVW (to Ser, Thr, Asp 555 
or Glu) were also recognised by CD8+ T cells in donor H008/4. Therefore, the number of 556 
amino acid variants alone cannot explain the variation in cross-reactive responses seen 557 
here, and the reasons for this remain to be determined.  558 
 559 
A limitation of our study is that the healthy JEV-exposed donors were older than the 560 
recovered JE patients. Practically, it is difficult to draw blood from children who have not 561 
been ill in this setting. Nevertheless, both groups were well matched for viral exposure, 562 
likely were exposed to JEV years earlier with ongoing exposure year on year, and we are 563 
not drawing direct comparisons between the two groups. Our within-group comparison of 564 
outcome from JE does not suffer from this limitation. Ideally the two groups should be 565 
matched for the time elapsed since first exposure to JEV, although within groups we could 566 
not observe a signal indicating a change in responsiveness of cross-reactivity over 567 
time/age (unpublished data). The optimum way to address this question would be using a 568 
prospective study design, but given the high rate of asymptomatic JEV infection, relatively 569 
low incidence of JE, and existence of many other conditions which are hard to differentiate 570 
from JE, such a study would be impractical. 571 
 572 
A second shortcoming is the small number of subjects with peptide mapping and cross-573 
reactive T cell response data, despite the screening of larger numbers. Although the 574 
clinical setting introduces some limitations, our data demonstrate a clear lack of cross-575 
reactive responses in recovered JE patients. A technical concern of our cross-reactivity 576 
experiments was that these were not conducted on optimally defined peptides, as optimal 577 
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T cell epitopes located within a larger peptide can affect detection of the response 578 
(Draenert et al., 2004). The need to deconvolute the peptide pools in quick succession 579 
using single T cell lines, making maximal use of scarce samples, precluded minimal 580 
epitope mapping and HLA restriction in each case. Despite this, cross-reactive responses 581 
were readily detectable using library peptides. Because of the closed-ended nature of the 582 
HLA class I peptide binding groove, this would reduce detection of cross-reactive CD8+ T 583 
cell responses more than CD4+, the converse of what we have observed. Lastly, we 584 
justified the use of short term T cell lines by showing in a subset of donors that cross-585 
reactive responses ex-vivo correlated well with cross-reactive responses in T cell lines. 586 
 587 
In summary, using the first full breadth analysis of T cell responses to JEV in humans, we 588 
have demonstrated that a high quality IFNγ dominated CD4+ T cell response is associated 589 
with good recovery from JE in humans. JEV T cell responses are dominated by broadly 590 
cross-reactive CD8+ T cells in most healthy JEV-exposed donors. Cross-reactive 591 
responses in recovered JE patients, on the other hand, are much less frequent, though 592 
uncertainty remains regarding the true significance of this finding. In much of South and 593 
Southeast Asia, where JEV and DENV co-circulate, the effect of JEV immune responses 594 
could be significant in subsequent natural infection and in response to vaccines. 595 
Therefore, the sequence and timing of flavivirus infections and their effect on 596 
immunopathogenesis and potentially vaccine responses are worthy of further study. In the 597 
context of the current outbreak of Zika virus, this cross-reactivity at the T cell level, as we 598 
have identified here, could be of relevance to disease pathogenesis. 599 
 600 
 601 
 602 
  603 
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Materials and Methods 604 
 605 
Setting 606 
 607 
The study was conducted at the Indian Institute of Science (IISc) and National Institute for 608 
Mental Health and Neuroscience (NIMHANS) in Bangalore and Vijayanagar Institute of 609 
Medical Sciences (VIMS), Bellary; all in Karanataka State, India. Karnataka is endemic for 610 
JE; the disease occurs in rural areas but is uncommon in districts around Bangalore. 611 
Recovered JE patients were therefore recruited at VIMS medical centre. For most 612 
experiments, blood samples were transported overnight by train for processing in a 613 
laboratory in Bangalore. 614 
 615 
Study subjects 616 
 617 
Healthy donors with no history of neurological illness were recruited at IISc, NIMHANS and 618 
VIMS. Recovered JE patients were recruited at dedicated outpatient clinics held at the 619 
VIMS Medical Centre. Healthy donors were taken from family members of patients and 620 
other members of the local community. JE patients were drawn from previous cohorts 621 
studied in this location (Lewthwaite et al., 2010b; Lewthwaite et al., 2010c), recruited 622 
based on hospital records of positive CSF JEV IgM samples and follow up of acute JE 623 
cases recruited during the study period (October 2011 to March 2013). All recovered JE 624 
patients had been admitted to VIMS medical centre with a clinical illness compatible with 625 
encephalitis (fever plus one of the following: clouding of consciousness, seizures or focal 626 
neurological signs) and a positive enzyme linked immunosorbent assay for JEV IgM in 627 
CSF. Patients had been admitted a median of 6 years earlier (mean 5.98, range 6 months 628 
to 14 years). A small cohort was also recruited in the UK. Age, sex, travel history/previous 629 
area of residence, flavivirus vaccine history and medical history (focused on flavivirus 630 
illness) was collected from all participants. Recovered JE patients underwent detailed 631 
neurological examination and disability assessment using the Liverpool outcome score 632 
(Lewthwaite et al., 2010a).  633 
 634 
Ethics statement 635 
 636 
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This study was carried out in accordance with the principles of the declaration of Helsinki. 637 
The experimental studies in India were approved by the IISc Institutional Human Ethics 638 
Committee (IHEC, ref 5/2011). All Indian studies were also approved by the Liverpool 639 
school of Tropical Medicine research ethics committee (ref 10.59). The component of the 640 
study conducted at VIMS medical centre was further reviewed by the VIMS ethics 641 
committee. The UK set up phase of the study was approved by the National Research 642 
Ethics Committees Northwest 7 (NREC NW7, ref 10/H1008/23). All participants gave 643 
informed consent, or their parent/guardian gave consent if aged under 18. Minors aged 12 644 
to 18 were able to give assent in addition to the guardian’s consent if they wished. 645 
 646 
Peptide libraries 647 
 648 
All available JEV complete genome sequences in the NCBI nucleotide database were 649 
downloaded in April 2010. Open reading frames were translated, aligned, and a 650 
consensus amino acid sequence was generated using Se-AL carbon v2.0a11 651 
(http://tree.bio.ed.ac.uk/software/seal/). Because only JEV genotype III was identified as 652 
circulating in South India until April 2010 the sequence used for the JEV peptide library 653 
was the consensus sequence of JEV genotype III. However, genotype III sequences 654 
predominated in the database and a consensus sequence generated using all the 655 
available sequences was identical. The JEV consensus sequence was used to generate a 656 
library of peptides 18 amino acids long overlapping by 10. In addition, if the C terminal 657 
amino acid residue of the peptide was not an HLA class I anchor residue the peptide was 658 
truncated until an “allowed” residue was reached or until a length of 15 amino acids (the 659 
overlap was kept constant at 10) to improve the sensitivity for CD8+ responses (Draenert 660 
et al., 2003; Draenert et al., 2004). Peptides were synthesised by Mimotopes Ltd as a 661 
PepSet™ (Supplementary information). Peptides were dissolved in dimethyl sulphoxide 662 
(DMSO) and pooled as indicated. The following peptide sets were obtained through 663 
Biodefense and Emerging Infection (BEI) Resources, NIAID, NIH: DENV1 664 
Singapore/S275/1990 E (NR4551), NS1 (NR2751), NS3 (NR2752) NS5 (NR4203); 665 
DENV2 New Guinea C (NGC) C (NR505), prM (NR506), E (NR507), NS1 (NR508), NS2a 666 
(NR2747), NS2b (NR2748), NS3 (NR509), NS4a (NR2749), NS4b (NR2750), NS5 667 
(NR2746); DENV3 Sleman 1978 E (NR511), DENV3 Philippines/H87/1956 NS1 (NR2753), 668 
NS3 (NR2754), NS5 (NR4204); DENV4 Dominica/814669/1981 E (NR512), DENV4 669 
Singapore/8976/1995 NS1 (NR2755), NS3 (NR2756) NS5 (NR4205); West Nile vrus 670 
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NY99-flamingo382-99 C (NR432), prM (NR433), M (NR434), E (NR435), NS1 (NR436), 671 
NS2a (NR437), NS2b (NR438), NS3 (NR439), NS4a (NR440), NS4b (NR441) and NS5 672 
(NR442). BEI resources peptides were dissolved using the same strategy as for JEV. 673 
 674 
IFNγ ELISpot assay 675 
 676 
ELISpot assays were performed using anti-human IFNγ capture and biotinylated detection 677 
antibodies from Mabtech, according to the manufacturers instructions. Development was 678 
by detection with goat anti-biotin-HRP and NBT/BCIP one step substrate (Fisher). PBMC 679 
were plated at 2 x 105 per well and incubated overnight in 100μl RPMI supplemented with  680 
2mM L-glutamine, 100U/ml penicillin and 0.1mg/ml streptomycin (sRPMI) with 10% fetal 681 
calf serum (FCS, R10), and peptides at a final concentration of 3-6μg/ml. The positive 682 
control was concanavalin A at a final concentration of 5μg/ml, negative control was DMSO 683 
at equivalent concentration to the peptide pools. 684 
 685 
ELISpot assays were considered positive if there were at least 50 spot forming cells 686 
(SFC)/106 PBMC and double the background value. In cases close to the cut-off value, 687 
confirmation by another assay or mapping to a peptide was used. In 7 JEV antibody 688 
negative UK residents, no subject gave a response using these criteria, and studies on 689 
other members of the family Flaviviridae have used similar/idenitcal thresholds (Appanna 690 
et al., 2007; Barnes et al., 2012; Parsons et al., 2008). Healthy donors were screened 691 
using 11 pools of peptides (1 pool for C/prM, 2 for E, 1 each for NS1 & NS2, 2 for NS3, 1 692 
for NS4 and 3 for NS5). Recovered JE patients, where available samples were smaller, 693 
were screened using 6 pools as indicated in Fig 1 A-C. For the healthy donors, responses 694 
to adjacent pools that were above the threshold were summed to create data comparative 695 
to the 6 pools used in recovered JE patients. Pools which did not reach the cut-off value 696 
were considered to be zero to prevent the creation of apparent responses by addition of 697 
two sub-threshold values. 698 
 699 
Carboxyfluorescein succinimidyl ester (CFSE) labelling and proliferation assays 700 
 701 
PBMC were used fresh or thawed and rested overnight. Eight to 10 million PBMC were 702 
labelled with CFSE (Molecular probes, Life Technologies) at a concentration of 1μM in 1ml 703 
pre-warmed PBS in the dark at 37°C for 10 minutes. Labelling was terminated by addition 704 
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of 5 volumes of ice cold R10 followed by incubation on ice for 3-4 minutes. Labelled cells 705 
were washed twice then plated at 0.5 million cells per well in 250μl sRPMI with 10% 706 
human serum (Valley Biomedical, California, USA), and stimulated with peptide pools at a 707 
final concentration of 3μg/ml. The positive control was concanavalin A at a final 708 
concentration of 2.5μg/ml, negative control was DMSO at equivalent concentration to the 709 
peptide pools. Cells were incubated for 8 days with removal and replacement of 75μl 710 
medium for cytokine assay after 48 h and 5 days. After incubation the cells were stained 711 
with near infra-red (IR) cell viability marker (Molecular probes, Life Technologies), fixed in 712 
2% formaldehyde in PBS then frozen at -80°C in 1% BSA, 10% DMSO in PBS until 713 
analysis by flow cytometry. Prior to analysis cells were stained with CD3 Alexa Fluor 700 714 
(clone UCHT-1), CD4 PE (clone RPA-T4), CD8 APC (clone RPA-T8) and CD38 PE-Cy7 715 
(clone HIT2); all from BD Pharmingen. Responses were considered positive if there were 716 
at least 1% of cells in the CD4+ or CD8+ gate were CFSElo/CD38hi and this value was at 717 
least double the background. 718 
 719 
Ex-vivo peptide stimulation and intracellular cytokine staining (ICS) 720 
 721 
Whole blood was stimulated with JEV peptide pools in the presence of 10μg/ml brefeldin A 722 
(Sigma Aldrich) and incubated for 6h in a water bath at 37°C using the field-suitable 723 
method of Hanekom et al. that does not require a CO2 incubator (Hanekom et al., 2004). 724 
Power interruptions were frequent at VIMS but the ambient temperature was 34-35°C, so 725 
the water bath maintained ≥36°C, within the normal range of human body temperature 726 
(Mackowiak et al., 1992). After 6 hours the stimulation was stopped by placing the tubes 727 
on ice followed by transport back to Bangalore the same night. Subjects studied in 728 
Bangalore followed an identical protocol with a 6 hour stimulation terminated by placing 729 
the samples at 4°C overnight. Red blood cells were lysed the following morning. Freshly 730 
isolated PBMC were stimulated with peptides overnight, 10μg/ml brefeldin A was added 731 
after 1 hour. PMA (25ng/ml) and ionomycin (250ng/ml) (both Sigma Aldrich) served as the 732 
positive control; the negative control was the equivalent concentration of DMSO to the 733 
peptide pools. Cells stimulated by either method were stained with near IR cell viability 734 
marker then fixed and frozen prior to analysis. Cells were permeabilised (BD Perm/Wash) 735 
and stained with CD3 (clone UCHT-1), CD4 (clone RPA-T4), CD8 (clone RPA-T8), IFNγ 736 
(clone 4S.B3), TNFα (clone MAb11), IL2 (clone 5344.111), macrophage inflammatory 737 
protein (MIP)-1β (clone D21-1351) and CD14 APC-Cy7 (clone MφP9, dump channel). In 738 
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some experiments CD107a (clone H4A3) was  added at the start of the stimulation to 739 
assess for degranulation (Betts et al., 2003). Anti-MIP-1β was from R&D systems, all other 740 
antibodies were from BD Pharmingen. Cells were acquired on a BD Canto II cytometer 741 
with photomultiplier tube voltages set using a single batch of setup & tracking beads (BD 742 
Bioscience) throughout. Data were analysed using FlowJo v8.8.6 (TreeStar), 743 
polyfunctional T cell distributions were analysed and presented using SPICE v5.35, with 744 
pre-processing in Pestle v1.7 (Roederer et al., 2011). The SPICE statistical function 745 
“compare pies” was used for comparison of T cell function patterns (Fig 6 C). 746 
 747 
Whole blood ICS (WB ICS) responses were considered positive if the responding 748 
population was at least 0.02% of the parent gate and double the background (example 749 
data are given in Fig 2 A). Background was subtracted prior to analysis. 750 
 751 
Expansion of short term T cell lines 752 
 753 
Short term T cell lines were expanded to JEV peptide pools or individual peptides showing 754 
ex vivo responses. Fresh or frozen rested PBMC were stimulated with peptide pools at 755 
3μg/ml (up to a maximum of 1% DMSO). Where responding peptides were known, 756 
10μg/ml peptide was used to expand cells for cross-reactivity assays. Cells were cultured 757 
at 2 million cells per well in 24 well plates in 1ml of RPMI with 10% human serum, 10% 758 
Natural T cell growth factor/IL2 (“T-stim”) (Helvetica healthcare) and 20ng/ml IL7 (R&D 759 
systems) for 8 to 10 days. Before assay the cells were rested overnight in R10 then 760 
stimulated with peptides or pools of peptides for 6 hours in the presence of brefeldin A. 761 
Cells were fixed, permeablised, stained and analysed by flow cytometry using the same 762 
method as for ex vivo ICS. 763 
 764 
Cytotoxicity assay 765 
 766 
Cytotoxicity assays were conducted as previously described (Kurioka et al., 2015). Briefly, 767 
appropriately HLA matched peptide loaded B cell lines were used as target cells and 768 
labelled with CFSE according to the manufacturer’s protocol. Cells were pulsed with 769 
peptide at the indicated concentrations for one hour followed by three washes with R10. 770 
Non-peptide pulsed cells were labelled with Cell Trace Violet (CTV, Molecular probes). 771 
Pulsed and unpulsed cells were mixed in a 1:1 ratio and incubated with peptide specific 772 
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short term T cell lines for 4 hours at an effector:target ratio of 10:1 in duplicates. CD107a 773 
(clone H4A3) was added at the start of the stimulation. Following incubation, cells were 774 
stained with near-IR viability marker, CD3 (clone UCHT1; eBioscience), CD8 (clone RPA-775 
T8; eBioscience), and CD19 (clone LT19; Miltenyi Biotec). The average % survival of 776 
CFSE labelled cells in wells containing no effectors was used to calculate the expected 777 
frequency of target cells in each well: expected ratio (ER) was calculated as % CFSE+/% 778 
CTV+.  The specific killing was then calculated as: 779 
 780 
% Specific killing = 100 x [(ER x % CTV+ cells) - % CFSE+ cells]/(ER x % CTV+ cells). 781 
 782 
HLA typing 783 
 784 
HLA typing was done using commercially available kits at the TTK Rotary blood bank, 785 
Bangalore (India) or the Churchill Hospital, Oxford (UK). Not all subjects in the cohort were 786 
HLA typed, typing focused on those subjects where peptides were mapped. HLA class I A, 787 
B and class II D related (DR) typing was done on subjects who showed predominantly 788 
CD4 responses, and HLA class I A, B and C typing was done on those showing 789 
predominantly CD8 responses. 790 
 791 
HLA class I peptide tetramers 792 
 793 
HLA class I peptide tetramers were supplied by the NIH tetramer core facility. JEV peptide-794 
tetramers were labelled with PE and variant peptide-tetramers were labelled with APC. 795 
The reagents used were: HLA B*58:01-MTTEDMLQVW-PE (JEV NS5 809 - 818), HLA 796 
B*58:01-MTTEDMLSVW-APC (DENV1 NS5 803 - 812), HLA B*58:01-MTTEDMLTVW-797 
APC (DENV2/3 NS5 804 - 813) and HLA B*58:01-MTTEDMLEVW-APC (WNV NS5 808 - 798 
817). Fresh viable PBMC or T cell lies were stained for 30 minutes at 37°C before being 799 
stained with cell viability maker and other surface antibodies as described in the ICS 800 
method. Cells were fixed prior to analysis on a BD LSR II cytometer. 801 
 802 
Bead array 803 
 804 
Supernatants collected from proliferation assays on day 2 and day 5 were assayed using 805 
the Bio-Plex 14-plex human cytokine/chemokine kit (Bio-Rad) on the Bio-Plex 200 platform 806 
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according to the manufacturers instructions. Supernatants were selected on the basis of 807 
the largest proliferation responses per subject. Responses were considered positive if the 808 
value secreted was at least double the amount detected from unstimulated cells and the 809 
background was subtracted before analysis. 810 
 811 
Viruses and cell lines 812 
 813 
JEV 0423 (derived from SA14-14-2), DENV1 16007, DENV2 16681, DENV3 16562, 814 
DENV4 C0036/06, C6/36 cells and LLC-monkey kidney (MK)2 cells for use in 50% plaque 815 
reduction neutralisation titre (PRNT50) determination were supplied by AFRIMS virology 816 
dept, Bangkok. JEV P20778, used for screening assays, and PS cells were grown in 817 
house at NIMHANS, Bangalore. LLC-MK2 cells were maintained in M199 medium, C6/36 818 
and PS cells were maintained in minimum essential medium (MEM). All media were 819 
supplemented with 2mM L-glutamine, 10% FCS and 100U/0.1mg/ml 820 
penicillin/streptomycin. LLC-MK2 cells and PS cells were maintained at 37°C with 5% CO2, 821 
C6/36 cells were maintained at 28°C with 5% CO2. All viruses were passaged once prior to 822 
use in C6/36 cells, titred and stored in aliquots at -80°C. Epstein Barr virus transformed 823 
HLA types B cell lines for HLA restriction experiments were kindly provided by Prof. Philip 824 
Goulder, University of Oxford, Oxford, UK. 825 
 826 
Plaque reduction neutralisation titres 827 
 828 
Sera of healthy donors were screened for JEV NAb by incubating 2-fold dilutions down to 829 
1 in 16 of heat inactivated sera with 100 plaque forming units (PFU) of JEV P20778 for 830 
one hour at 37°C. Mixtures were inoculated onto monolayers of PS cells with rocking at 831 
37°C for one hour to allow virus adsorption followed by removal of inoculum and addition 832 
of minimum essential medium (MEM) with 2% FCS and 1% low melting point (LMP) 833 
agarose. After three days, destruction of the monolayer was assessed by crystal violet 834 
staining after fixing with 10% formalin in saline for 30 minutes. PRNT50 were subsequently 835 
assayed in a subset by a standard method (Russell et al., 1967). Briefly, heat inactivated 836 
sera were diluted serially four-fold from 1 in 10 to 1 in 2650, incubated with 30-50 PFU of 837 
JEV or DENV1 to 4 at 37°C for one hour then inoculated onto duplicate monolayers of 838 
LLC-MK2 cells with rocking at room temperature (25-28°C) for one hour followed by 839 
removal of inoculum and addition of 1ml phenol red free overlay medium with 0.9% LMP 840 
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agarose. Plates were incubated for 4 days (JEV, DENV1 and DENV3), 6 days (DENV4) or 841 
7 days (DENV2) prior to addition of a further 1ml overlay medium containing 4% neutral 842 
red. Plaques were visualised and counted after a further 24 hours incubation. PRNT50 was 843 
calculated by probit regression. 844 
 845 
Statistical and bioinformatic methods 846 
 847 
All statistical analyses were done using R version 3.1.2 (www.r-project.org). Differences 848 
between non-parametric unpaired variables were assessed with a two-sided Mann 849 
Whitney U (Wilcoxon rank sum) test. Categorical variables across groups were assessed 850 
by Fisher’s exact test. Correlations between ex-vivo and in-vitro expanded T cell 851 
responses were assessed by Spearman’s test. P values < 0.05 were considered 852 
significant. Shannon entropy of aligned JEV and DENV polyprotein sequences was 853 
calculated using the protein variability server of the Immunomedicine group, Universidad 854 
Complutense, Madrid (http://imed.med.ucm.es/PVS/) (Garcia-Boronat et al., 2008). 855 
Sequence data were obtained from the NIAID Virus Pathogen Database and Analysis 856 
Resource (ViPR) online through the web site at http://www.viprbrc.org by searching for all 857 
JEV and DENV complete genomes restricted to India as country of origin (Pickett et al., 858 
2012). The polyprotein sequences of the JEV and BEI resources DENV1 to 4 peptide 859 
libraries used were also included. Nucleic acid sequences were downloaded, edited to 860 
remove 5’ and 3’ untranslated regions and translated using SeaView v4.4.2 (Gouy et al., 861 
2010). Polyprotein alignments were performed using ClustalW (Larkin et al., 2007). HLA-862 
peptide binding predictions were conducted using the software of the Bioinformatics and 863 
Molecular Analysis Section (BIMAS), NIH (http://www-bimas.cit.nih.gov/molbio/hla_bind/); 864 
SYFPEITHI (http://www.syfpeithi.de/) and HLArestrictor 1.2 Server 865 
(http://www.cbs.dtu.dk/services/HLArestrictor/) (Erup Larsen et al., 2011; Parker et al., 866 
1994; Rammensee et al., 1999). 867 
 868 
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Figures 1114 
 1115 
 1116 
Figure 1. Breadth of the T cell response to peptide pools of JE virus in JEV-exposed 1117 
healthy donors. 1118 
(A) Relative frequency of ex-vivo IFNγ responses were measured by ELISpot or 1119 
intracellular cytokine staining (ICS) in JEV-exposed healthy donors (n = 35, 29 ELISpot 1120 
and 6 ICS). Peptide pools are shown grouped by viral proteins (C = core, prM = pre 1121 
membrane, E = envelope, NS = non-structural protein). For a subset of 5 subjects ICS and 1122 
ELISpot was performed at least three times with consistent results. (B) Spot forming cells 1123 
(SFC) per million PBMC were measured by ELISpot in 13 healthy JEV-exposed donors 1124 
(18 responses, black circles) and three DENV exposed subjects (four responses, red 1125 
triangles). (C) Proliferative responses were measured by CFSE dilution and flow cytometry 1126 
Page 36 
in healthy JEV-exposed donors once per subject. Data are relative frequency (n = 24) for 1127 
CD4+ (grey bars) and CD8+ T cells (open bars).  (D) Based on data from ICS assays the 1128 
proportion of the total IFNγ response produced by CD8+ T cells in each healthy JEV-1129 
exposed donor was calculated; bar depicts the median.  1130 
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Figure 2. CD8+ T cell responses are highly flavivirus cross-reactive in healthy JEV-1132 
exposed donors. 1133 
(A) ICS assays were used to detect IFNγ+/TNFα+ cells from healthy JEV-exposed donor 1134 
H008/4. Example flow cytometry data from an ex-vivo assay (top panels) and a short term 1135 
T cell line (bottom panels) show responses to variant peptides of JEV NS5 1136 
MTTEDMLQVW, gated on live, CD3+, CD8+ cells, representative of three experiments. 1137 
Similar results were obtained with DENV4 and West Nile virus (WNV) peptides (not 1138 
depicted). Axes are log10 fluorescence units. (B) IFNγ responses to peptide titrations of the 1139 
same NS5 peptides in (A) and WNV peptide MTTEDMLEVW were measured by ex-vivo 1140 
ELISpot, representative of two independent experiments. (C) Cytokine (IFNγ+, TNFα+ or 1141 
MIP-1β+ in any combination) responses to NS3 peptide titrations of JEV, DENV1-4 and 1142 
YFV presented on a B cell line (BCL) matched for HLA B*08:01 were measured by ICS. 1143 
Responding cells were CD8+ T cell lines (TCL) from a subject reporting dengue illness, 1144 
yellow fever vaccination but not JEV exposure (H001/4), expanded with JEV (left panel) or 1145 
DENV (right panel) peptides, each assayed against all three peptides. Black diamonds 1146 
indicate peptide with no BCL. Open squares indicate a peptide pulsed HLA-mismatched 1147 
BCL. Peptide titrations by ex-vivo ELISpot or ICS gave similar results and expansion of T 1148 
cell lines from two further independent samples showed equal cross-reactivity. (D) 1149 
IFNγ+/TNFα+ cells of a CD8+ T cell line from healthy JEV-exposed donor H007/3 were 1150 
measured by ICS to a JEV NS5 peptide and the DENV variant peptides indicated, showing 1151 
epitope conservation in variant peptides. The same experiment was performed twice ex-1152 
vivo with similar results. (E) Cross-reactivity of ex-vivo responses and short term T cell 1153 
lines were measured by ICS. Cross-reactivity index (variant response ÷ JEV response 1154 
from the same assay) between JEV and DENV1-4/WNV in 5 subjects of ex-vivo 1155 
measurements correlated with T cell lines (Spearman’s R = 0.62, p = 0.002). Ex-vivo 1156 
assays were performed at least twice in all donors except one with similar results. (F) 1157 
Cross-reactivity of short term T cell lines expanded with JEV peptides with WNV and 1158 
DENV1-4 was measured by ICS. Data are cross-reactivity indices as in (E) of all T cell 1159 
responses identified in healthy JEV-exposed donors. Wilcoxon signed rank tests showed 1160 
no significant differences from a hypothetical value of 1 (indicating an equal response to 1161 
JEV and variant peptides); p = 0.06 (WNV), 0.68 (DENV1), 0.29 (DENV2), 0.79 (DENV3), 1162 
0.67 (DENV4). In two subjects these assays were repeated three times with good 1163 
agreement. (G) CD8+ T cells from donor H008/4 were stained with with JEV peptide-HLA 1164 
class I tetramers (x axis) and variant peptide tetramers (y axis) and analysed by flow 1165 
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cytometry. Data are representative of two independent experiments. (H) CD8+ T cells were 1166 
tetramer stained and analysed as in (G). Titrations of three different tetramers are shown: 1167 
JEV (MTTEDMLQVW, blue), WNV (MTTEDMLEVW, yellow) and DENV2+3 1168 
(MTTEDMLTVW, purple, common epitope). Data are median fluorescence intensity (left) 1169 
and %CD8+ T cells stained (right). Repeating this experiment using a short term T cell line 1170 
expanded with JEV peptide gave similar results. (I) Neutralising antibodies against JEV 1171 
and all four DENV serotypes were measured by 50% plaque reduction (PRNT50). Bars 1172 
depict the median; four subjects had some assays repeated with similar results. 1173 
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Figure 3. Function of T cell responses to peptide pools of JE virus in healthy JEV-1175 
exposed donors. 1176 
(A) Whole blood ICS (WB ICS) assays were used to measure cytokine+ cells from 11 1177 
healthy JEV-exposed donors. Example data from a WB ICS experiment (donor H014/3) 1178 
are shown. Axes are log10 fluorescence units. Top panels: IFNγ vs TNFα, bottom panels: 1179 
IFNγ vs MIP-1β. (B) WB ICS data were analysed using Simplified Presentation of 1180 
Incredibly Complex Evaluations (SPICE) software for ten donors; one donor did not have 1181 
the full flow cytometry panel performed. Bars indicate median and interquartile range 1182 
(IQR); pie slices indicate the fraction of response of the group that expresses four 1183 
cytokines (red), three (orange), two (yellow) and one (blue) in any combination. (C) 1184 
Magnitude of CD4+ and CD8+ WB ICS IFNγ+/TNFα+ responses in healthy JEV-exposed 1185 
donors measured by ICS (n = 11, 15 CD8+ and 3 CD4+ T cell responses). IFNg, IFN-1186 
gamma; MIP-1b, MIP-1beta.  (D) Secreted cytokine concentrations were measured by 1187 
bead array from 12 healthy JEV-exposed donors after 5 days of stimulation with JEV 1188 
peptide pools. The heatmap depicts log10 transformed pg/ml. Some subjects had >1 1189 
peptide pool assayed. Data are depicted after subtraction of values obtained from 1190 
unstimulated cells. This experiment was performed once. (E) Relative frequency of 1191 
secreted cytokine responses from the same data in (D) after 2 and 5 days of stimulation 1192 
with JEV peptide pools. Subjects were considered positive if any pool was positive at 1193 
either time-point.  1194 
 1195 
  1196 
4%
 C
D
8+
 T
 c
el
l r
es
po
ns
e
3 2 1No. of functionsper cell
Pie Slice
TNF
MIP-1b
IFNg
CD107a
0
20
40
60
+
+
+
+
+
+
+
-
+
+
-
+
+
-
+
+
-
+
+
+
+
+
-
-
+
-
+
-
+
-
-
+
-
+
+
-
-
+
-
+
-
-
+
+
+
-
-
-
-
+
-
-
-
-
+
-
-
-
-
+ Virus: JEV
Virus: DENV
Pie Chart Arc Legend
CD107a +
Bar Chart Legend
Virus: JEV
Virus: DENV
JEV
n = 6
7 peptides
DENV
n = 4
15 peptides
I
A
0 -9 -8 -7 -6 -5
10-2.5
10-2
10-1.5
10-1
10-0.5
Log g/ml peptide
%
 C
D
10
7a
+ 
C
D
8+
 T
 c
el
ls
-5-6-7-8-9-100
10-2
10-1.8
10-1.6
10-1.4
10-1.2
10-1
10-0.8
Log10 molar peptide
-5-6-7-8-9-10-11
0.00
0.02
0.04
0.06
0.08
0.10
DENV peptide
JEV peptide
Log10 molar peptide
Natural JEV exposure Dengue illness
Donor H001/1 Donor H008/4
Donor H001/4
C
E
JE
V
JE
V
DE
NV
1
DE
NV
2
DE
NV
3
DE
NV
4
0.01
0.1
1
10
Natural JEV exposure
Dengue
illness
Test
peptideJEV DENV
Exposure
n = 2 n = 7 n = 4 n = 5 n = 4n = 3
Test peptide:
%
 C
D
10
7a
+ 
C
D
8+
 T
 c
el
ls
! Recovered
JE patient
? Dengue
illness
B
IFN
γ+
CD
10
7a
+
0.0
0.2
0.4
0.6
0.8
1.0 !/" = JEV
!/" = DENV
Fr
ac
tio
n 
of
 re
sp
on
di
ng
 C
D
8+
 T
ce
lls
  t
ha
t a
re
 g
ra
nz
ym
e 
B+
F
D
H
G
-9 -8 -7 -6
0
20
40
60
Log10 molar peptide
%
 s
pe
ci
fic
 k
illi
ng
-9 -8 -7 -6
0
5
10
15
20 JEV peptide
DENV peptide
JEV DENVTCL to:
Log10 molar peptide
%
 C
D
10
7a
+ 
 C
D
8+
 T
 c
el
ls
-9 -8 -7 -6
0
20
40
60
80
Log10 molar peptide
%
 s
pe
ci
fic
 k
illi
ng
-9 -8 -7 -6
10
15
20
25
30
35 DENV2/3 peptide
DENV1 peptide
JEV peptide
JEV DENV 2/3TCL to:
Log10 molar peptide
%
 C
D
10
7a
+ 
 C
D
8+
 T
 c
el
ls
H008/4 (natural JEV exposure) H001/4 (dengue fever)
J
Page 40 
Figure 4. CD8+ T cell responses from JEV-exposed donors show a cytotoxic 1197 
phenotype. 1198 
(A) Degranulation of CD8+ T cells in response to JEV and DENV variant peptides was 1199 
measured by CD107a staining/flow cytometry. Representative data from one of two 1200 
experiments in healthy JEV-exposed donor (H008/4). (B) Degranulation responses to 1201 
variant flavivirus peptides were measured as in (A) in naturally JEV-exposed subjects (n = 1202 
7; 6 healthy, 1 recovered JE patient) and subjects reporting dengue illness (recovered JE 1203 
and dengue illness are indicated). (C) Degranulation responses were measured as in (A) 1204 
to titrations of JEV and DENV variant peptides in two healthy JEV-exposed donors 1205 
(H001/1, left panel, H008/4, centre panel) and a subject reporting dengue illness (H001/4, 1206 
right panel). (D, E) JEV specific CD8+ T cells were identified by IFNγ ICS and co-stained 1207 
for (D) perforin and (E) granzyme B. Representative data from one (perforin, JE054/2; 1208 
granzyme B H008/4) of four subjects are shown. (F) IFNγ+/granzyme B+ and 1209 
CD107a/granzyme B+ double positive CD8+ T cells were detected in the same 1210 
experiments as (D & E) in one healthy JEV-exposed and two dengue-exposed donors in 1211 
response to all peptides tested; four JEV (black) and two DENV peptides (red). (G) 1212 
Degranulation of a short term T cell line from a healthy JEV-exposed donor (H007/2) in 1213 
response to JEV and DENV variant peptides measured as in (A), representative of five 1214 
donors tested. (H) Data from the same experiment as (G) showing cross-reactivity for 1215 
DENV peptides. Cross-reactivity was observed in two independent experiments, one 1216 
included CD107a staining. (I) CD8+ T cell IFNγ, TNFα, MIP-1β, and CD107a responses 1217 
were measured by ICS and analysed using SPICE. Six healthy JEV-exposed donors (7 1218 
JEV responses), four of whom had variant DENV peptides tested (15 DENV peptides), 1219 
were included. In two subjects repeat experiments showed similar results. Bars indicate 1220 
median and IQR, pie slices the fraction of response showing four (red), three (orange), two 1221 
(yellow) and one (blue) function(s) in any combination. (J) Peptide pulsed, CFSE labelled, 1222 
HLA matched targets were incubated with CD8+ T cell line effector cells and % specific 1223 
killing was measured by flow cytometry in response to JEV (blue) and DENV (red/purple) 1224 
peptides. Peptides were: donor H001/4, DVMCHATL (JEV) and DLMCHATF (DENV); 1225 
donor H008/4 MTTEDMLQVW (JEV), MTTEDMLSVW (DENV1) and MTTEDMLTVW 1226 
(DENV2/3). Diamonds indicate lines expanded with JEV peptide, squares DENV peptide, 1227 
assays were performed once for each T cell line/peptide pair. 1228 
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Figure 5. Breadth of the T cell response to JEV peptide pools in recovered JE 1230 
patients. 1231 
(A) WB ICS assays were used to measure cytokine+ cells in recovered JE patients, 1232 
example flow cytometry data from four patients are shown. Axes are log10 fluorescence 1233 
units. Top panels: CD8+ responses, IFNγ vs TNFα (left panels) IFNγ vs MIP-1β (right 1234 
panels); bottom panels: CD4+ responses, IFNγ vs TNFα (left panels) and IL2 vs TNFα 1235 
(right panels). (B) Ex-vivo IFNγ responses from 39 recovered JE patients were measured 1236 
by ELISpot (n = 17) or ICS (n = 22) and relative frequency of responses to each peptide 1237 
pool was calculated. (C) Relative proportion of the cytokine response produced by CD4+ T 1238 
cells in individual patients was measured by ICS in the same experiments as (A) and (B); 1239 
bar depicts the median. (D) Proliferation responses were measured by CFSE dilution and 1240 
flow cytometry in 18 recovered JE patients of whom 15 showed responses; relative 1241 
frequency for CD4+ T cells (grey bars) and CD8+ T cells (open bars) is shown. (E) 1242 
Proliferative responses from the same experiments as (D) were equal in size between 1243 
good outcome (open bars) and poor outcome (hatched bars) for CD4+ cells (25 responses 1244 
in 8 patients with good outcome and 13 responses in 4 patients with poor outcome, p = 1245 
0.4, Mann Whitney U test); CD8+ responses were larger in poor outcome (23 responses in 1246 
8 patients with good outcome and 17 responses in 6 patients with poor outcome, p = 1247 
0.012). Bars depict median and IQR, whiskers 1.5 x IQR and outliers are shown as points. 1248 
(F) Cross-reactivity of short term T cell lines expanded with JEV peptides with WNV and 1249 
DENV1-4 was measured by ICS. Data are cross-reactivity indices (as per Fig 2 E) of 14 T 1250 
cell responses identified in 7 recovered JE patients. Wilcoxon signed rank tests showed 1251 
significant differences from a hypothetical value of 1 (i.e. the response to JEV and variant 1252 
peptides was not equivalent) for all viruses except DENV1; p = 0.036 (WNV), 0.055 1253 
(DENV1), 0.002 (DENV2), 0.011 (DENV3), 0.004 (DENV4). (G) Neutralising antibodies 1254 
against JEV and all four DENV serotypes were measured by 50% plaque reduction 1255 
(PRNT50). Bars depict the median; assays were generally performed once per person, 1256 
nine subjects had some assays repeated with similar results. (H) JEV PRNT50 were the 1257 
same in JE patients with good (n = 9) and poor (n = 7) outcome (p = 0.84, Mann Whitney 1258 
U test). Bars depict the median and IQR. 1259 
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Figure 6. T cell cytokine responses to JEV peptide pools in recovered JE patients. 1262 
Recovered JE patients showing CD4+ T cell responses were categorised into good 1263 
outcome (complete recovery, n = 16) and poor outcome (recovery with residual 1264 
neurological deficit/disability > 6 months after disease, n = 11). Cytokine responses were 1265 
measured by WB ICS once per subject; 30 responses were detected in the good outcome 1266 
group and 22 responses in the poor outcome group. (A) IFNγ responses were smaller in 1267 
those with poor outcome (p = 0.015, Mann Whitey U test). (B) TNFα responses showed no 1268 
difference with outcome (p = 0.32, Mann Whitey U test). (C) CD4+ T cell responses were 1269 
analysed using SPICE according to outcome from JE. Patients with poor outcome had 1270 
fewer polyfunctional cells (p < 0.0001, SPICE compare pies function, 10 000 replicates), 1271 
with the difference largely accounted for by IFNγ+/TNFα+/IL2+ cells (p = 0.001, Mann 1272 
Whitney U test); and more TNFα+ cells (p < 0.0001). Data in (C) were analysed for 1273 
individual responses; summing by subjects retained the strong significance of the result. 1274 
(D) Secreted cytokine concentrations were measured by bead array from 11 recovered JE 1275 
patients after 5 days of stimulation with JEV peptide pools. The heatmap depicts log10 1276 
transformed pg/ml. Some subjects had >1 peptide pool assayed. Data are depicted after 1277 
subtraction of values from unstimulated cells and are displayed according to outcome from 1278 
JE (top, good outcome n = 7; bottom, poor outcome, n = 4). This experiment was 1279 
performed once. (E) Relative frequency of secreted cytokine responses from the same 1280 
experiments as (D) after 2 and 5 days of stimulation with JEV peptide pools. Subjects were 1281 
considered positive if any pool was positive at either time point. (F) CD8+ T cell responses 1282 
from recovered JE patients were assayed once per subject by WB ICS (n = 14, 18 1283 
responses) and analysed using SPICE. (G) There was no difference in years since 1284 
admission with clinical JE and sampling for this study between the good and poor outcome 1285 
groups (p = 0.35, Mann Whitney U test). 1286 
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Figure 7. Peptide epitopes of JEV identified in healthy JEV-exposed donors, 1289 
recovered JE patients and DENV exposed donors. 1290 
Peptide were identified in ICS assays of short term T cell lines expanded with peptide 1291 
pools showing ex-vivo responses, or by ex-vivo ELISpot. Both peptides that have been 1292 
mapped down to the minimal epitope (8 peptides) and library peptides of 15-18 amino 1293 
acids in are shown. CD4+ responses are green, CD8+ blue. Location of peptide responses 1294 
in (A) healthy JEV-exposed donors (n = 11), (B) recovered JE patients (n = 12) and (C) 1295 
two subjects reporting dengue illness. Three peptides in common between JE patients and 1296 
either healthy group are marked by dotted lines. (D) Shannon entropy (H index) was 1297 
calculated using all the available DENV and JEV complete polyprotein sequences from 1298 
India (13 DENV1 sequences, 10 DENV2 sequences, 8 DENV3 sequences, 5 DENV4 1299 
sequences and 8 JEV sequences), and the sequences of the DENV1-4 and JEV peptide 1300 
libraries used in this study. The H index varies from 0, corresponding to a single conserved 1301 
amino acid residue at that position, to 4.322, where all 20 amino acids are represented 1302 
equally. (E) Schematic representation of JEV proteins corresponding to their size. (F) 1303 
Average Shannon entropy (H Index) of flavivirus regions corresponding to 15 unique 1304 
peptides identified in the healthy JEV-exposed group and 25 unique peptides identified in 1305 
the recovered JE group (using the same virus polyprotein sequences in (D)) was 1306 
significantly lower in the epitopes identified from recovered JE patients (p = 0.0003, Mann 1307 
Whitney U test). Bars depict median and IQR, whiskers 1.5 x IQR and outliers are shown 1308 
as points. 1309 
  1310 
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TABLE I. Characteristics of the study participants 
 
  
  
Recovered JE 
patients 
Healthy, JEV 
NAb positive 
Indian controls 
Healthy, JEV 
NAb negative 
Indian controls 
UK cohort 
N 
  39 35 16 13 
Median age (range) 13 (1 -25) 26 (7 - 55) 25 (22 - 55) 26 (23 - 60) 
Sex 22M, 17F 24M, 11F 10M, 6F 7M, 6F 
Years since JE 6 (0.5 - 12) NA NA NA 
Number tested for DENV NAb 14 14 3 8 
DENV NAb positive (any serotype) 14 14 3 3 
Dengue illness 0 3 0 4 
Residence in a JE endemic area All All All 1 
Travel to a JE endemic area NA NA NA 8 
JE vaccine 0 0 0 6a 
Liverpool 
outcome score 
5 24 
NA NA NA 4 5 3 7 
2 3 
 
The Liverpool outcome score is a five-point score grading recovery from encephalitis in 
children and adolescents (Lewthwaite et al., 2010a). 5 = full recovery, 4 = minor disability, 
3 = moderate disability, 2 = severe disability, 1 = death (not applicable here). Six subjects 
in the UK cohort received JE vaccine (a), four before and two during the study period. 
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TABLE II. JEV peptides eliciting T cell responses identified in this study 
 
Subject Peptide Subset JEV protein 
Amino acid 
location Type 
HLA 
Restriction  HLA Class I  HLA Class II 
              A B C DR 
JE082/2 
GKNRAINMLKRGLPRVF CD4 C 9 - 25 JE  11:01, 33:01 13:01, 44:02  DR12, DR14, DR52 VFPLVGVKRVVMSLLDGR CD4 C 24 - 41  
JE093/2 MLKRGLPRVFPLVGVKRVVMSLLDGR CD4 C 16 - 41 JE  24:02, 24:02 13:01, 27:02  DR15, DR51 
JE043/2 SLVNKKEAWLDSTKATRY CD8 M 230 - 247 JE  01:01, 11:01 52:01, 57:01  DR3, DR15, DR52, DR51 
 WIIRNPGYAFLAAVLGWM CD4 M 254 - 271       
JE101/2 RYLMKTENWIIRNPGYAF CD4 M 246 - 263 JE  30:01, 33:01 13:01, 44:02  DR7, DR53 
JE017/2 
AKFSCTSKAIGRTIQ CD4 E 411 - 425 
JE 
 
03:01, 11:02 07:02, 35:01  DR4, DR11, DR52, DR53 
KQSVVALGSQEGGLHQAL CD4 E 543 - 560  
CRLKMDKLALKGTTYGMCTEKFSF CD4 E 581 - 604  
HGTVVIELSYSGSDGPCK CD4 E 613 - 630  
LGKAFSTTLKGAQRLAAL CD4 E 697 - 714  
WDFGSIGGVFNSIGKAVHQVFGGAF CD4 E 719 - 735  
GVLVFLATNVHADTGCAI CD4 E 783 - 801  
H021/1 PWTSPSSTAWRNRELLM CD4 E 518 - 534 HC  02:01, 11:01 07:02, 52:01  DR15, DR51 
JE003/2 
KYLPETPRSLAKIVHK CD4 + CD8 NS1 827 - 842 
JE 
 
03:01, 33:01 15:01, 37:01  DR10, DR15, DR51 AVHSDLSYWIESRYNDTWKLERAVF CD4 NS1 987 - 1011  
WIESRYNDTWKLERAVFGEVKSCTW CD4 NS1 995 - 1019  
JE001/2 EAWVDRYKYLPETPRSLAKIVHK CD4 NS1 820 - 842 JE  11:01, 31:01 35:01, 52:21  DR4, DR15, DR53, DR51 TYALNTFTNIAVQLVRLM CD8 NS5 3136 - 3153  
H014/3 TAVLAPTRVVAAEMAEAL CD8 NS3 1723 - 1740 HC  03:01, 30:01 07:02, 13:01 06:02, 07:01  
H001/1 ALRGLPVRY CD8 NS3 1739 - 1747 HC  11:01, 32:01 15:01, 55:01 01:02, 04:01  
H001/4 DVMCHATL CD8 NS3 1763 - 1770 D B*08:01 01:01, 03:01 08:01, 44:02 05:01, 07:01 DR8, DR17, DR52 
H019/1 NLFVMDEAHFTDPASI CD8 NS3 1784 - 1799 HC  02:01 38:01, 40:06 07:01, 15:02  EAHFTDPASIAARGYI CD8 NS3 1790 - 1805  
H013/3 
NLFVMDEAHFTDPASI CD4 NS3 1784 - 1799 
HC 
 
02:01, 24:02 35:03, 40:06 02:21, 15:02  EAHFTDPASIAARGYI CD4 + CD8 NS3 1790 - 1805  
GEAAAIFMT CD8 NS3 1812 - 1820  
JE098/2 ELGEAAAIFMTATPP CD8 NS3 1810 - 1824 JE  02:01 35:01, 40:06 04:01, 07:01  
H005/1 GCGRGGWSYYAATLKKV CD8 NS5 2608 - 2624 HC  02:01, 30:01 13:01, 38:01 06:02, 12:02  RGYTKGGAGHEEPMLM CD8 NS5 2628 - 2643  
H010/4 
LMQSYGWNL CD8 NS5 2642 - 2650 
D 
 
01:01, 02:01 08:01, 35:01 04:01, 07:01  
LVSLKSGVDVFYKPS CD8 NS5 2650 - 2664  
YMPKVIEKMEV CD8 NS5 2714 - 2724  
NMTSQVLLGRMDRTVWR CD8 NS5 2761 - 2777  
HPYRTWTY CD8 NS5 2827 - 2834 B*35:01 
TPFGQQRVF CD4 + CD8 NS5 2873 - 2884  
JE080/2 KLNAMSREEFFKYRREAIIEVDR CD4 NS5 2542 - 2564 JE  02:01, 33:01 15:05, 44:02  DR7, DR53 TWHKDPEHPYRTWTYHGSYEVK CD4 NS5 2820 - 2841  
Page 46 
H007/2 TMAMTDTTPFGQQRVFK CD4 + CD8 NS5 2869 - 2885 HC  01:01, 68:01 57:01  DR53, DR7 
H011/3 TMAMTDTTPFGQQRVFK CD8 NS5 2869 - 2885 HC  02:01, 68:01 37:01, 51:01 06:02, 15:02  
H007/3 
TMAMTDTTPFGQQRVFK CD4 + CD8 NS5 2869 - 2885 
HC 
 
11:01, 68:01 07:02, 52:02 07:01, 12:02  CTKEEFIKKVNSNAAL CD8 NS5 2923 - 2938  
DIAGKQGGKMYADDTAGW CD4 NS5 3050 - 3067  
H002/3 IWFMWLGARY CD8 NS5 3003 - 3012 HC  01:01, 29:01 07:05, 57:01 06:02, 15:04  RYLEFEALGFL CD4 NS5 3011 - 3021  
JE054/2 AISGDDCVVKPLDDRFATALHFL CD8 NS5 3191 - 3213 JE  11:01, 24:02 15:25, 51:01 07:01, 16:01  
JE074/2 CVVKPLDDRFATALHFL CD8 NS5 3197 - 3213 JE      
H008/4 MTTEDMLQVW CD4 + CD8 NS5 3336 - 3345 HC B*58:01 01:01, 33:03 58:01, 15:17 07:01, 03:04 DR13, DR15, DR51, DR52 CSAVPVDW CD8 NS5 3312 - 3319 B*58:01 
JE446/2 
  
GEWMTTEDMLQVWNRVWI CD4 NS5 3333 - 3350 JE 
  
 01:01, 33:01 
  
52:01, 58:01 
    
DR14, DR15, DR52, 
DR51 
  MLQVWNRVWIEENEWMM CD8 NS5 3341 - 3357   
 
In total 57 responses to 40 peptides (or adjacent pairs of peptides) were identified. JE = recovered JE patient; H = healthy JEV exposed donor; D 
= dengue exposed. 
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TABLE III. Variant peptides eliciting T cell responses. 
 
JEV Peptide sequence Subject type 
Viruses with 
identical 
sequence 
Subset Variant Virus/BEI peptide location 
CSAVPVDW H DENV1 CD8 CSSVPVDW MVEV 
MTTEDMLQVW H 
 
CD8 
MTTEDMLRVW JEV 
MTTEDMLSVW DENV1 
MTTEDMLTVW DENV2+3 
MTTEDMLKVW DENV4 
MTTEDMLEVW WNV, YFV 
MTTEDMLDVW TBEV 
ALRGLPVRY H ZIKV CD8 ALRGLPIRY WNV, DENV2+4 
NLFVMDEAHFTDPASI 
EAHFTDPASIAARGYI  H DENV2+3 CD8 
NYNMIIMDEAHFTDPA DENV1 NS3 p49 
IMDEAHFTDPASIARRG DENV1 NS3 p50 
NYNLIIMDEAHFTDPASI DENV2 NS3 p38 
NYNLIIMDEAHFTDPA DENV3 NS3 p48 
PNYNLIVMDEAHFTD DENV4 NS3 p49 
LIVMDEAHFTDPSSVAA DENV4 NS3 p50 
AHFTDPSSVAARGYIST DENV4 NS3 p51 
TMAMTDTTPFGQQRVFK H WNV CD4+CD8 
MVTQIAMTDTTPFGQQRa DENV1 NS5 p60 
AMTDTTPFGQQRVFKEKa DENV2 NS5 p61 
MVTQMAMTDTTPFGQQRa DENV3 NS5 p60 
MVTQLAMTDTTPFGQQRa DENV4 NS5 p60 
GEAAAIFMT H WNV, DENV1,3+4, ZIKV CD8 MGEAAAIFMTATPPGSV
a DENV1 NS3 p54, DENV3 NS3 p52 
    VEMGEAAAIFMTATPPGa DENV4 NS3 p54 
TAVLAPTRVVAAEMAEAL H WNV CD8 
NVRTLILAPTRVVASEM DENV1 NS3 p38 
LRTLILAPTRVVAAEM DENV2 NS3 p30 
TLILAPTRVVAAEMEEA 
DENV3 NS3 p38, 
DENV4 NS3 p39 
DVMCHATL D WNV, MVEV, SLEV CD8 DLMCHATF DENV1-4, ZIKV DAMCHATL YFV 
AVHSDLSYWIESRYNDTW JE  CD4 NLAIHSDLSYWIESRL WNV NS1 p26 
WIESRYNDTWKLERAVF JE  CD4 
RLNDTWKLERAVLGEVK WNV NS1 p28 
IESEKNETWKLARASFI DENV NS1 p36 
KQSVVALGSQEGGLHQAL JE 
 
CD4 
HATKQSVIALGSQEGALH WNV E p34  
ALGSQEGALHQALAGAI WNV E p35 
VVVLGSQEGAMHTALTG DENV1 E p44 
HAKKQDVVVLGSQEGAMH DENV2 E p34  
VLGSQEGAMHTALTGA DENV2 E p35  
HAKKQEVVVLGSQEGAMH DENV3 E p35, DENV1b 
VLGSQEGAMHTALTGA DENV3 E p36, 
HAKRQDVTVLGSQEGAMH DENV4 E p36  
VLGSQEGAMHSALAGA DENV4 E p37  
HGTVVIELSYSGSDGPCK JE  CD4 HGTVVLELQYTGTDGPCK WNV E p44 
LGKAFSTTLKGAQRLAAL JE  CD4 
HKSGSSIGKAFTTTLKGA WNV E p55 
KAFTTTLKGAQRLAAL WNV E p56 
WDFGSIGGVFNSIGKAV JE  CD4 
WDFGSVGGVFTSVGKAVH WNV E p59 
GVFNSIGKAVHQVFGGAF VFTSVGKAVHQVFGGAFR WNV E p60 
AISGDDCVVKPLDDRF 
CVVKPLDDRFATALHFL 
  
JE 
  
CD4+CD8 
AVSGDDCVVKPLDDRFA WNV NS5 p91+92c VVKPLDDRFATSLHFLNA 
ISGDDCVVKPIDDRFAT DENV1 NS5 p115+116c VVKPIDDRFATALTALN 
ISGDDCVVKPLDDRFA DENV2 NS5 p116+117c CVVKPLDDRFASALTAL 
MAISGDDCVVKPIDDRF DENV3 NS5 p115+116c DCVVKPIDDRFANALLA 
MAISGDDCVVKPLDERF DENV4 NS5 p116+117c DCVVKPLDERFSTSLLF 
 
Variant peptides were synthesised or obtained from BEI resources; their location within each 
peptide set (see materials and methods) is given in the last column. Bold/underlined amino 
acids represent differences from the JEV sequence. a = Likely to represent conserved epitope 
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DTTPFGQQR (see Fig 2 D). b = Identical viral sequences, but corresponding peptides vary 
slightly. c  = Pairs of peptides tested together in the same assay. JE = recovered JE patient, H = 
healthy JEV exposed, D = dengue exposed. MVEV = Murray Valley encephalitis virus, WNV= 
West Nile virus, YFV = yellow fever virus, TBEV = tick borne encephalitis virus, SLEV = St. 
Louis encephalitis virus, ZIKV = Zika virus. 
 
 
 
 
 
 
 
